A Phase 3 interventional study of contezolid acefosamil (IV)/contezolid (PO) and Linezolid (IV and PO) in Diabetic Foot Infection, sponsored by MicuRx. Recruiting at 14 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by MicuRx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Approximately 865 subjects (519 contezolid acefosamil/contezolid: 346 linezolid) will be enrolled with moderate or severe DFI that are confirmed or suspected to be due to a Gram-positive bacterial pathogen (MITT analysis set).
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
This study's planned enrollment of 865 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Browse Diabetic Foot studies →MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: contezolid acefosamil (IV)/contezolid (PO)
Drug: Linezolid (IV and PO)
Drug page: ContezolidStudies of ContezolidContezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Drug page: LinezolidStudies of LinezolidLinezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators
The primary objective is to evaluate the Investigator's assessment of clinical response at the D35 visit in subjects receiving contezolid acefosamil/contezolid compared to subjects receiving linezolid in the MITT analysis
Time frame: Day 35
Adverse events - symptoms reported by subjects
Evaluate safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)
Time frame: 28-35 days after End-of-Therapy (EOT)
Clinical laboratory assessment - complete blood count
Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)
Time frame: 28-35 days after End-of-Therapy (EOT)
Vital signs - heart rate
Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)
Time frame: 28-35 days after End-of-Therapy (EOT)
Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators
Evaluate the Investigator's assessment of clinical response at EOT visit in the MITT analysis set
Time frame: 14-28 days
Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators
Evaluate the Investigator's assessment of clinical response at Day 10 (D10) and Late Follow-Up visits (LFU; 28-35 days after EOT) in the MITT analysis set
Time frame: Day 10, 28-35 days after EOT
Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.
Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 61 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Contezolid
MicuRx